Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB047986 in Primary MDS Refractory to ESAs
NCT02093429Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INCB047986 in myelodysplastic syndrome (MDS), sponsored by Incyte. Started Jan 2014; status: terminated.
02
Drugs
INCB047986
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02093429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093429.